Verona Pharma plc (VRNA) Bundle
A Brief History of Verona Pharma plc (VRNA)
Company Overview
Verona Pharma plc is a clinical-stage biopharmaceutical company focused on respiratory diseases. The company is listed on NASDAQ under the ticker VRNA.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Cash and Cash Equivalents | $93.8 million (as of September 30, 2023) |
| Research and Development Expenses | $44.8 million (for nine months ended September 30, 2023) |
| Net Loss | $54.0 million (for nine months ended September 30, 2023) |
Key Product Pipeline
- Ensifentrine (RPL554): Primary focus for treating COPD and asthma
- Phase 3 clinical trials ongoing for COPD treatment
- Potential first-in-class inhaled dual PDE3 and PDE4 inhibitor
Stock Performance
| Stock Metric | 2024 Value |
|---|---|
| Stock Price (as of January 2024) | Approximately $1.50-$2.00 per share |
| Market Capitalization | Approximately $100-$150 million |
Corporate Developments
Key Strategic Focus: Advancing ensifentrine through clinical development for respiratory diseases
Regulatory Status
- FDA Fast Track Designation for ensifentrine in COPD
- Ongoing Phase 3 clinical trials for COPD treatment
A Who Owns Verona Pharma plc (VRNA)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage |
|---|---|---|
| Consonance Capital Management LP | 4,352,500 | 13.4% |
| Baker Bros. Advisors LP | 3,950,000 | 12.2% |
| Orbimed Advisors LLC | 3,725,000 | 11.5% |
Top Institutional Investors
- Consonance Capital Management LP: $42.3 million invested
- Baker Bros. Advisors LP: $38.7 million invested
- Orbimed Advisors LLC: $36.5 million invested
Ownership Structure
As of Q4 2023, Verona Pharma plc (VRNA) has 32.4 million outstanding shares. Institutional investors own approximately 62.7% of total shares.
Public Float
Public float represents 37.3% of total outstanding shares, which translates to approximately 12.1 million shares.
Verona Pharma plc (VRNA) Mission Statement
Company Overview
Verona Pharma plc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases.
Financial Performance
| Market Capitalization (as of January 2024) | $170.2 million |
| Cash and Cash Equivalents (Q3 2023) | $115.3 million |
| Research and Development Expenses (2022) | $87.6 million |
Key Product Pipeline
- Ensifentrine: Primary respiratory drug targeting COPD and asthma
- Phase 3 clinical trials in progress for COPD treatment
- Novel dual PDE3/PDE4 inhibitor
Strategic Focus Areas
Primary therapeutic areas of concentration:
- Chronic Obstructive Pulmonary Disease (COPD)
- Asthma management
- Respiratory disease innovation
Research Investment
| R&D Investment Percentage (2022) | 68% of total operating expenses |
| Patent Portfolio | 22 granted patents worldwide |
Regulatory Status
Current clinical development stage: Advanced Phase 3 trials for lead respiratory therapy
Shareholder Information
| Stock Exchange Listing | NASDAQ (VRNA) |
| Share Price Range (2023) | $1.50 - $3.25 |
How Verona Pharma plc (VRNA) Works
Company Overview
Verona Pharma plc is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases.
Key Product Pipeline
| Product | Indication | Development Stage |
|---|---|---|
| Ensifentrine | COPD | Phase 3 Clinical Trials |
| Ensifentrine Inhalation Solution | Bronchodilation | Phase 2 Clinical Trials |
Financial Performance
As of Q4 2023, Verona Pharma reported:
- Cash and cash equivalents: $138.1 million
- Research and development expenses: $54.3 million
- Net loss: $64.2 million
Research Strategy
Verona Pharma concentrates on developing novel phosphodiesterase inhibitors targeting respiratory diseases.
Therapeutic Focus Areas
- Chronic Obstructive Pulmonary Disease (COPD)
- Asthma
- Respiratory inflammatory conditions
Corporate Structure
Headquartered in London, United Kingdom, with research facilities in Durham, North Carolina, USA.
Stock Information
| Exchange | Ticker Symbol | Market Cap |
|---|---|---|
| NASDAQ | VRNA | $327.5 million |
How Verona Pharma plc (VRNA) Makes Money
Revenue Streams
Verona Pharma plc generates revenue primarily through its lead drug candidate, ensifentrine, which targets respiratory diseases.
| Product | Market Potential | Development Stage |
|---|---|---|
| Ensifentrine | $1.2 billion COPD market | Phase 3 clinical trials |
Financial Performance
As of Q3 2023, Verona Pharma reported:
- Cash and cash equivalents: $118.3 million
- Research and development expenses: $37.4 million
- Net loss: $42.5 million
Key Product Development
Verona Pharma focuses on developing ensifentrine for:
- Chronic obstructive pulmonary disease (COPD)
- Bronchiectasis
- Cystic fibrosis
| Indication | Potential Patients | Market Size |
|---|---|---|
| COPD | 16 million US patients | $20.3 billion by 2026 |
| Bronchiectasis | 110,000 US patients | $1.5 billion by 2025 |
Funding Strategy
Verona Pharma raises capital through:
- Public offerings
- Equity financing
- Grants and collaborations
Total funding raised since 2019: $250 million
Verona Pharma plc (VRNA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.